Both the IDH1 inhibitor Ivosidenib and the IDH2 inhibitor Enasidenib can restore differentiation in IDH-mutated AML cells, and their clinical efficacy led to FDA approval for these genetically defined AML subtypes [137, 140]. The gene discussed is IDH2; the disease is acute myeloid leukemia.